Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

One-year follow-up of CD19/BCMA dual-targeting fastcar-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus

View Full Paper
Ask AI
Bookmark
Share

Authors

JFJingjing FengXFXintong FengSFShan Fu

Discussion

Loading...

Member takes

Overview

Open-label trial finds CAR-T therapy improves autoantibody levels and remission in patients with refractory lupus, suggesting potential for deeper immune reset.

Key Points

  • To evaluate the safety and efficacy of GC012F therapy in patients with refractory systemic lupus erythematosus.
  • Open-label, single-arm study
  • Enrolled patients with refractory SLE who failed multiple therapies
  • Administered GC012F after lymphodepletion with follow-up on safety and efficacy measures
  • 14 out of 15 patients showed B cell depletion and reconstitution within 56 days
  • 60% of patients achieved DORIS remission by 1 year
  • Notable improvements in autoantibody levels and SLEDAI scores observed

Cite This Study

Feng et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236ddbbhttps://doi.org/10.1182/blood-2025-2384
View Full Paper
Ask AI
Bookmark
Share